Serotonin reuptake transporter deficiency modulates the acute thermoregulatory and locomotor activity response to 3,4-(±)-methylenedioxymethamphetamine, and attenuates depletions in serotonin levels in SERT-KO rats

Toxicological Sciences

Volumn 139, Issue 2, 2014, Pages 421-431

  Lizarraga, Lucina E ^a   Phan, Andy V ^a   Cholanians, Aram B ^a   Herndon, Joseph M ^a   Lau, Serrine S ^a   Monks, Terrence J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Locomotor activity; MDMA; Neurotoxicity; SERT; Thermoregulation

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; SEROTONIN; SEROTONIN TRANSPORTER; SLC6A4 PROTEIN, RAT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BODY TEMPERATURE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; HYPERACTIVITY; LOCOMOTION; MALE; NERVE ENDING; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; RAT; RAT MODEL; REDUCTION; SEROTONIN RELEASE; SEROTONIN REUPTAKE TRANSPORTER DEFICIENCY; THERMOGENESIS; THERMOREGULATION; VELOCITY; ANIMAL; BRAIN; DEFICIENCY; DRUG EFFECTS; GENE SILENCING; GENETICS; METABOLISM; MOTOR ACTIVITY; NEUROTOXICITY SYNDROMES; PATHOPHYSIOLOGY; TIME; TOXICITY; WISTAR RAT;

ANIMALS; BODY TEMPERATURE; BODY TEMPERATURE REGULATION; BRAIN; GENE KNOCKDOWN TECHNIQUES; HYDROXYINDOLEACETIC ACID; MALE; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROTOXICITY SYNDROMES; RATS, WISTAR; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TIME FACTORS;

EID: 84899913909     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfu039     Document Type: Article

References (44)

1. Ball, K. T., Budreau, D., and Rebec, G. V. (2003). Acute effects of 3,4-methylenedioxymethamphetamine on striatal single-unit activity and behavior in freely moving rats: Differential involvement of dopamine D1 and D2 receptors. Brain Res. 994, 203-215.
2. Ball, K. T., and Rebec, G. (2005). Role of 5-HT2A and 5-HT2C/B receptors in the acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on striatal single-unit activity and locomotion in freely moving rats. Psychopharmacology 181, 676-687.
3. Benstaali, C., Mailloux, A., Bogdan, A., Auzéby, A., and Touitou, Y. (2001). Circadian rhythms of body temperature and motor activity in rodents: Their relationships with the light-dark cycle. Life Sci. 68, 2645-2656.
4. Berger, U. V., Gu, X. F., and Azmitia, E. C. (1992). The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, pchloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur. J. Pharmacol. 215, 153.
5. Blakely, R. D., De Felice, L. J., and Hartzell, H. C. (1994). Molecular physiology of norepinephrine and serotonin transporters. J. Exp. Biol. 196, 263-281.
6. Bolla, K. I., McCann, U. D., and Ricaurte, G. A. (1998). Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology 51, 1532-537.
7. Broening, H. W., Bowyer, J. F., and Slikker, W., Jr (1995). Agedependent sensitivity of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J. Pharmacol. Exp. Ther. 275, 325-333.
8. Callahan, B. T., Cord, B. J., and Ricaurte, G. A. (2001). Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine. Synapse 40, 113-121.
9. Clineschmidt, B. V., Totaro, J. A., McGuffin, J. C., and Pflueger, A. B. (1976). Fenfluramine: Long-term reduction in brain serotonin (5-hydroxytryptamine). Eur. J. Pharmacol. 35, 211-214.
10. 2+-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br. J. Pharmacol. 121, 1735-1743.
11. Dafters, R. I. (1994). Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or "ecstacy") in rats. Psychopharmacology 114, 505-508.
12. Fischer, C., Hatzidimitriou, G., Wlos, J., Katz, J., and Ricaurte, G. (1995). Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). J. Neurosci. 15, 5476-5485.
13. Fitzgerald, J.L., and Reid, J. J. (1993). Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices. Naunyn Schmiedebergs Arch. Pharmacol. 347, 313-323.
14. Fuller, R. W. (1980). Mechanism by which uptake inhibitors antagonizepchloroamphetamine-induced depletion of brain serotonin. Neurochem. Res. 5, 241-245.
15. Gudelsky, G. A., and Nash, J. F. (1996). Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: Implications for serotonindopamine interactions. J. Neurochem. 66, 243-249.
16. Hashimoto, K., Maeda, H., and Goromaru, T. (1992). Effects of benzylpiperazine derivatives on the neurotoxicity of 3,4-methylenedioxymethamphetamine in rat brain. Brain Res. 590, 341-344.
17. Homberg, J. R.,De Boer, S. F., Raaso, H. S., Olivier, J. D., Verheul, M., Ronken, E., Cools, A. R., Ellenbroek, B. A., Schoffelmeer, A. N., Vanderschuren, L. J., et al. (2008). Adaptations in pre-and postsynaptic 5-HT1A receptor function and cocaine supersensitivity in serotonin transporter knockout rats. Psychopharmacology (Berl.) 200, 367-380.
18. Homberg, J. R., Olivier, J., Smits, B.M. G., Mul, J. D., Mudde, J., Verheul, M., Nieuwenhuizen,O. F.M., Cools, A. R., Ronken, E., Cremers, T., et al. (2007). Characterization of the serotonin transporter knockout rat: A selective change in the functioning of the serotonergic system. Neuroscience 146, 1662-1676.
19. Johnson, M. P., Hoffman, A. J., and Nichols, D. E. (1986). Effects of enantiomers of MDA, MDMA and related analogues on 3H serotonin and 3H dopamine release from superfused rat brain slices. Eur. J. Pharmacol. 132, 269-276.
20. Liechti, M. E., Baumann, C.,Gamma, A., andVollenweider, F.X. (2000).Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22, 513-521.
21. Malberg, J. E., and Seiden, L. S. (1998). Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J. Neurosci. 18, 5086-5094.
22. Marston, H. M., Reid, M. E., Lawrence, J. A., Olverman, H. J., and Butcher, S. P. (1999). Behavioral analysis of the acute and chronic effects of MDMA treatment in the rat. Psychopharmacology 144, 67-76.
23. Mechan, A. O., Esteban, B., O'Shea, E., Elliott, J. M., Colado, M. I., and Green, A. R. (2002). The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br. J. Pharmacol. 135, 170-180.
24. Mills, E.M., Rusyniak, D. E., and Sprague, J. E. (2004). The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine. J. Mol. Med. (Berl.) 82, 787-799.
25. Murphy, D. L., Lerner, A., Rudnick, G., and Lesch, K. P. (2004). Serotonin transporter: Gene, genetic disorders, and pharmacogenetics. Mol. Interv. 4, 109-123.
26. Olivier, J. D., Van Der Hart,M. G., Van Swelm, R. P., Dederen, P. J., Homberg, J. R., Cremers, T., Deen, P. M., Cuppen, E., Cools, A. R., and Ellenbroek, B. A. (2008). A study in male and female 5-HT transporter knockout rats: An animal model for anxiety and depression disorders. Neuroscience 152, 573-584.
27. O'Hearn, E., Battaglia, G., De Souza, E. B., Kuhar, M. J., and Molliver, M. E. (1988). Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: Immunocytochemical evidence for neurotoxicity. J. Neurosci. 8, 2788-2803.
28. Palenicek, T., Votava, M., Bubenikova, V., and Horacek, J. (2005). Increased sensitivity to the acute effects of MDMA ("ecstasy") in female rats. Physiol. Behav. 86, 546-553.
29. Ricaurte, G., Bryan, G., Strauss, L., Seiden, L., and Schuster, C. (1985). Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 229, 986-988.
30. Ricaurte, G. A., Yuan, J., and McCann, U. D. (2000). (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: Studies in animals. Neuropsychobiology 42, 5-10.
31. Rothman, R. B., and Baumann, M. H. (2003).Monoamine transporters and psychostimulant drugs. Eur. J. Pharmacol. 479, 23-40.
32. Rothman, R. B., Baumann, M. H., Dersch, C. M., Romero, D. V., Rice, K. C., Carroll, F. I., and Partilla, J. S. (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39, 32-41.
33. Rudnick, G., and Clark, J. (1993). From synapse to vesicle: The reuptake and storage of biogenic amine neurotransmitters. Biochim. Biophys. Acta 4, 249-263.
34. Sanchez, V., Camarero, J., Esteban, B., Peter, M. J., Green, A. R., and Colado, M. I. (2001). The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine againstMDMA('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain. Br. J. Pharmacol. 134, 46-57.
35. Schloss, P., and Williams, D. C. (1998). The serotonin transporter: A primary target for antidepressant drugs. J. Psychopharmacol. 12, 115-121.
36. Schmidt, C. J. (1987). Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 240, 1-7.
37. Shioda, K., Nisijima, K., Yoshino, T., Kuboshima, K., Iwamura, T., Yui, K., and Kato, S. (2008). Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats. Neurotoxicology 29, 1030-1036.
38. Smits, B. M., Mudde, J. B., van de Belt, J., Verheul, M., Olivier, J., Homberg, J., Guryev, V., Cools, A. R., Ellenbroek, B. A., Plasterk, R. H., et al. (2006). Generation of gene knockouts and mutant models in the laboratory rat by ENU-driven target-selected mutagenesis. Pharmacogenet. Genomics 16, 159-169.
39. De Souza, E. B., Battaglia, G., and Insel, T. R. (1990). Neurotoxic effect of MDMA on brain neurons: Evidence from neurochemical and radioligand binding studies. Ann. N. Y. Acad. Sci. 600, 682-698.
40. Timar, J., Gyarmati, S., Szabo, A., and Furst, S. (2003). Behavioural changes in rats treated with a neurotoxic dose regimen of dextrorotatory amphetamine derivatives. Behav. Pharmacol. 14, 199-206.
41. Trigo, J. M., Renoir, T., Lanfumey, L., Hamon, M., Lesch, K.-P., Robledo, P., and Maldonado, R. (2007). 3,4-Methylenedioxymethamphetamine selfadministration is abolished in serotonin transporter knockout mice. Biol. Psychiatry 62, 669-679.
42. Walker, Q. D., Williams, C., Jotwani, R., Waller, S., Francis, R., and Kuhn, C. (2007). Sex differences in the neurochemical and functional effects of MDMA in Sprague-Dawley rats. Psychopharmacology 189, 435-445.
43. Wallinga, A. E., Grahlmann, C., Granneman, R. A., Koolhaas, J. M., and Buwalda, B. (2011). Gender differences in hyperthermia and regional 5-HT and 5-HIAA depletion in the brain following MDMA administration in rats. Brain Res. 1398, 13-20.
44. Xie, T., Tong, L., McLane, M. W., Hatzidimitriou, G., Yuan, J., McCann, U., and Ricaurte, G. (2006). Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology 31, 2639-2651.